Baxter International Inc. · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-11$22.27 RISE2026-05-04$16.62 PEAK2026-05-26$19.38 104d | -25.4% 82d | Missed | Missed | — | — | +16.6% 22d | Missed |
DROP2026-02-11$22.27 RISE2026-03-30$15.80 PEAK2026-05-26$19.38 104d | -29.1% 47d | Missed | Missed | — | — | +22.7% 57d | Missed |
DROP2025-07-25$29.22 RISE2025-11-20$17.42 PEAK2026-02-11$22.27 201d | -40.4% 118d | Missed | Missed | — | — | +27.8% 83d | Missed |
DROP2024-09-16$40.26 RISE2024-12-30$28.63 PEAK2025-03-07$36.57 172d | -28.9% 105d | Missed | Missed | — | — | +27.7% 67d | Missed |
DROP2024-04-09$42.83 RISE2024-08-13$34.51 PEAK2024-09-16$40.26 160d | -19.4% 126d | Missed | Missed | — | — | +16.7% 34d | Missed |
DROP2024-03-08$43.77 RISE2024-07-02$32.85 PEAK2024-09-16$40.26 192d | -24.9% 116d | Missed | Missed | — | — | +22.6% 76d | Missed |
DROP2023-07-20$49.29 RISE2023-10-12$31.71 PEAK2024-01-08$40.67 172d | -35.7% 84d | Missed | Missed | — | — | +28.3% 88d | Missed |
DROP2023-04-28$47.68 RISE2023-05-30$40.33 PEAK2023-07-20$49.29 83d | -15.4% 32d | Missed | Missed | — | — | +22.2% 51d | Missed |
DROP2022-11-30$56.53 RISE2023-03-17$37.58 PEAK2023-04-28$47.68 149d | -33.5% 107d | Missed | Missed | — | — | +26.9% 42d | Missed |
DROP2020-02-06$93.30 RISE2020-03-16$71.57 PEAK2020-04-20$94.14 74d | -23.3% 39d | Missed | Missed | — | — | +31.5% 35d | Missed |
Shares of healthcare company Baxter International (NYSE:BAX) fell 1% in the morning session after Citigroup downgraded the stock to Sell from Neutral and lowered its price target to $17.
Wondering whether Baxter International at around US$19.18 is a bargain or a value trap? This article walks through what the current price might actually imply. The stock has moved sharply in the short term, with a 10.9% gain over the past week and 5.6% over the past month, despite being down 1.6% year to date and declining 35.5% over the past year and 50.2% over three years. These moves sit against an ongoing evergreen interest in Baxter International as a large healthcare equipment company...
Wondering whether Baxter International at around US$19.18 is a bargain or a value trap? This article walks through what the current price might actually imply. The stock has moved sharply in the short term, with a 10.9% gain over the past week and 5.6% over the past month, despite being down 1.6% year to date and declining 35.5% over the past year and 50.2% over three years. These moves sit against an ongoing evergreen interest in Baxter International as a large healthcare equipment company...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Baxter International (BAX) shares are attempting a technical turnaround, breaking a multi-week downtrend that increasingly appears to have bottomed around $16. The stock currently carries an 8% “Sell” technical opinion from Barchart, but that’s down from 88% a week ago and 56% a month ago. Technical indicators show an aggressive...
Baxter International (BAX) shares are attempting a technical turnaround, breaking a multi-week downtrend that increasingly appears to have bottomed around $16. The stock currently carries an 8% “Sell” technical opinion from Barchart, but that’s down from 88% a week ago and 56% a month ago. Technical indicators show an aggressive...
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
The medical adhesives market is poised for growth driven by the rise in minimally invasive surgeries, demand for advanced wound care, and wearable tech. Key opportunities lie in developing smart, biocompatible, and eco-friendly options, especially in Asia, with a focus on internal medical applications and water-based technologies.Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Medical Adhesives Market, Till 2035: Distribution by Type of Resin, Type of Technology, Areas of Application, Type of Ente
Discover the top S&P500 movers in Thursday's pre-market session and stay informed about market dynamics.
Exploring the Latest 13F Filing and Investment Strategies
Exploring the Latest 13F Filing and Investment Strategies
Baxter International Inc. (BAX) Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsKevin Moran - Vice President...
Presenter SpeechTravis Steed [Audio Gap] Presentation of the morning. So welcome up next Baxter International. We are lucky to have Andrew Hider, President and CEO. This is our first time having a...
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Intravenous (IV) Fluid Bags Market size & share revenue was valued at approximately USD 2.82 Billion in 2025 and is expected to reach USD 3.01 Billion in 2026 and is expected to reach around USD 5.46 Billion by 2035, at a CAGR of 6.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Baxter International I
Baxter International (NYSE:BAX) held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BAX | +9.12% | -4.62% | -1.73% | -38.43% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.15% | +1.09% | +1.72% | -51.11% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | Ampofo William A. II | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | Craig Jeffrey A | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | McDonnell Michael R. | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | Shafer David Brent | Chair of the Board | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | MORRISON PATRICIA | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | SCHLICHTING NANCY M | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | Wendell Amy McBride | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-05-07 | Wilkes David S. | Director | A Grant / award | 12,836 | — | +$0 |
| 2026-03-10 | Grade Joel T. | EVP and CFO | F Tax withholding | 8,153 | $17.69 | −$144.2K |
| 2026-03-10 | Rasul Reazur | EVP,Group Pres,Healthcare | F Tax withholding | 12,674 | $17.69 | −$224.2K |
| 2026-03-10 | Rosenbloom David S. | EVP and General Counsel | F Tax withholding | 6,620 | $17.69 | −$117.1K |
| 2026-03-10 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | F Tax withholding | 2,848 | $17.69 | −$50.4K |
| 2026-03-10 | Zielinski Anita A | SVP, CAO and Controller | F Tax withholding | 1,932 | $17.69 | −$34.2K |
| 2026-03-03 | Zielinski Anita A | SVP, CAO and Controller | A Grant / award | 30,864 | — | +$0 |
| 2026-03-03 | Grade Joel T. | EVP and CFO | A Grant / award(deriv) | 103,448 | — | +$0 |
| 2026-03-03 | Grade Joel T. | EVP and CFO | A Grant / award | 42,735 | — | +$0 |
| 2026-03-03 | Rosenbloom David S. | EVP and General Counsel | A Grant / award(deriv) | 64,655 | — | +$0 |
| 2026-03-03 | Rosenbloom David S. | EVP and General Counsel | F Tax withholding | 1,336 | $19.69 | −$26.3K |
| 2026-03-03 | Rosenbloom David S. | EVP and General Counsel | A Grant / award | 26,709 | — | +$0 |
| 2026-03-03 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | A Grant / award(deriv) | 57,471 | — | +$0 |
| 2026-03-03 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | F Tax withholding | 1,852 | $19.69 | −$36.5K |
| 2026-03-03 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | A Grant / award | 23,742 | — | +$0 |
| 2026-03-03 | Rasul Reazur | EVP,Group Pres,Healthcare | F Tax withholding | 1,614 | $19.69 | −$31.8K |
| 2026-03-03 | Carlisle Cynthia | Executive Vice President, CHRO | A Grant / award(deriv) | 43,103 | — | +$0 |
| 2026-03-03 | Carlisle Cynthia | Executive Vice President, CHRO | A Grant / award | 11,871 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 0.37 | — | — |
| 2026-04-30 | 0.31 | 0.36 | +15.93% |
| 2026-02-12 | 0.54 | 0.44 | -17.80% |
| 2025-10-30 | 0.30 | -0.09 | -130.00% |
| 2025-07-31 | 0.61 | 0.59 | -3.28% |
| 2025-05-01 | 0.48 | 0.55 | +13.82% |
| 2025-02-20 | 0.53 | 0.58 | +9.62% |
| 2024-11-08 | 0.78 | 0.80 | +3.03% |
| 2024-08-06 | 0.66 | 0.68 | +2.68% |
| 2024-05-02 | 0.61 | 0.65 | +7.19% |
| 2024-02-08 | 0.86 | 0.88 | +1.76% |
| 2023-11-02 | 0.68 | 0.68 | +0.34% |
| 2023-07-27 | 0.60 | 0.55 | -8.34% |
| 2023-04-27 | 0.49 | 0.59 | +19.59% |
| 2023-02-09 | 0.94 | 0.88 | -6.06% |
| 2022-10-27 | 0.81 | 0.82 | +0.65% |